Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Omid Hamid

ResearcherPublications, citations & collaboration network
888
Works
85,023
Citations
98
h-index
317
i10-index
How has Omid Hamid's publication output changed over time?
ScholarIQpublication output · 2009–2015

Output grew200% over the shown period — from 1 works in 2009 to 3 in 2015.

1
1
1
1
3
20092012201320142015
What are the most-cited papers on Omid Hamid?
ScholarIQmost cited works
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
New England Journal of Medicine. 20128,035 CitationsOPEN ACCESS
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
New England Journal of Medicine. 20156,260 CitationsOPEN ACCESS
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean‐Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas
New England Journal of Medicine. 20155,885 CitationsOPEN ACCESS
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi
Nature. 20145,287 Citations
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss‐Schaap, Alain P. Algazi, Christine Mateus, Peter D. Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas
New England Journal of Medicine. 20133,407 CitationsOPEN ACCESS
Related on ScholarIQ
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Paper
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Paper
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Paper
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Paper
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Paper
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Paper
470M+ articles · free account